Granted Patent
B2
US 12,508,227 · App. 17/391,021 · Granted Dec 30, 2025
Dry powder compositions with magnesium stearate
Assignee:
Aspeya US Inc.
A61K9/145A61K9/0075A61K9/008A61K31/4365A61K31/616A61M15/0021A61M15/003A61M15/0035A61M15/0041A61M15/0086A61M16/14A61M11/003A61M15/0023A61M2202/064A61M2205/582A61M2206/16
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 μm to about 5 μm. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.
Claims (21)
1 . A drug delivery system, comprising:
a respirable dry powder composition; and
a dry powder inhaler,
wherein the dry powder inhaler comprises
a mouthpiece,
a reservoir for receiving the dry powder composition, and
an actuation member for making available the respirable dry powder composition, and
wherein the respirable dry powder composition comprises dry particles comprising acetylsalicylic acid (ASA), or a pharmaceutically acceptable salt thereof, co-micronized with magnesium stearate,
wherein the magnesium stearate is in an amount of about 0.05% (w/w) to about 0.5% (w/w) of the dry powder composition, and
wherein ASA stability maintains 95% or above after exposure to a condition selected from the group consisting of 15-20° C./35-45% RH, 20° C./40% RH, 30° C./60% RH, 40° C./75% RH, and 50° C./75% RH, for two weeks, four weeks, 30 days, a month, six weeks, eight weeks, or 12 months.
2 . The drug delivery system of claim 1 wherein the acetylsalicylic acid or a pharmaceutically acceptable salt thereof is present in the respirable dry powder composition in an amount of more than 50% by weight, based on a total weight of the respirable dry powder composition.
3 . The drug delivery system of claim 1 wherein the respirable dry powder further comprises an anticoagulant.
4 . The drug delivery system of claim 1 wherein the respirable dry powder further comprises clopidogrel.
5 . The drug delivery system of claim 1 wherein dry particles of the respirable dry powder composition have a mass median aerodynamic diameter (MMAD) of less than 20 μm.
6 . The drug delivery system of claim 1 wherein dry particles of the respirable dry powder composition have a volume median geometric diameter (VMGD) as measured by HELOS/RODOS at 1.0 bar of 30 μm or less.
7 . The drug delivery system of claim 1 wherein dry particles of the respirable dry powder composition have a fine particle fraction (FPF) of less than 5.0 μm of at least 20%.
8 . The drug delivery system of claim 1 wherein dry particles of the respirable dry powder composition have a DV90 less than 20 μm, a DV50 less than 7 μm, and a DV10 less than 2 μm.
9 . The drug delivery system of claim 1 wherein dry particles of the respirable dry powder composition have a geometric standard deviation (GSD) of about 2.5 μm or lower.
10 . The drug delivery system of claim 1 , comprising a dose of less than 81 mg of acetylsalicylic acid or a pharmaceutically acceptable salt thereof.
11 . The drug delivery system of claim 10 , wherein the dose of acetylsalicylic acid or a pharmaceutically acceptable salt thereof is 40 mg to 60 mg.
12 . The drug delivery system of claim 1 , wherein the respirable dry powder composition has an emitted dose of 75% or higher.
Assignments (3)
CONFIRMATION OF ASSIGNMENT
Recorded Apr 24, 2023
From: OTITOPIC INC.
To: VECTURA INC.
Reel/Frame 063448/0621 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 24, 2021
From: YADIDI, KAMBIZ
To: OTITOPIC INC.
Reel/Frame 057888/0584 →
Continuity (4)
Continuation
15716492
· Sep 26, 2017
Provisional Application
62562295
· Sep 22, 2017
References Cited (205)
US 4069819A
· Valentini et al.
· 1978
[cited by applicant]
US 4849417A
· Bertrand et al.
· 1989
[cited by applicant]
US 4995385A
· Valentini et al.
· 1991
[cited by applicant]
US 5006516A
· Helbig et al.
· 1991
[cited by applicant]
US 5327883A
· Williams et al.
· 1994
[cited by applicant]
US 5533502A
· Piper
· 1996
[cited by applicant]
US 5875776A
· Vaghefi
· 1999
[cited by applicant]
US 6884794B2
· Staniforth et al.
· 2005
[cited by applicant]
US 6979437B2
· Bartus et al.
· 2005
[cited by applicant]
US 6994842B2
· Lee et al.
· 2006
[cited by applicant]
US 7025059B2
· Pera
· 2006
[cited by applicant]
US 7041286B2
· Nerenberg
· 2006
[cited by applicant]
US 7089934B2
· Staniforth et al.
· 2006
[cited by applicant]
US 7189750B2
· Assaf et al.
· 2007
[cited by applicant]
US 7405207B2
· Leonard et al.
· 2008
[cited by applicant]
US 7431916B2
· Nilsson et al.
· 2008
[cited by applicant]
US 7435720B2
· Quay et al.
· 2008
[cited by applicant]
US 7516741B2
· Glusker et al.
· 2009
[cited by applicant]
US 7534914B2
· Koike et al.
· 2009
[cited by applicant]
US 7559325B2
· Dunkley et al.
· 2009
[cited by applicant]
US 7651770B2
· Berkland et al.
· 2010
[cited by applicant]
US 7682614B2
· Strober et al.
· 2010
[cited by applicant]
US 7744906B2
· Coates
· 2010
[cited by applicant]
US 8069851B2
· Dunkley et al.
· 2011
[cited by applicant]
US 8236786B2
· Finch et al.
· 2012
[cited by applicant]
US 8530463B2
· Cartt et al.
· 2013
[cited by applicant]
US 8561609B2
· Donovan et al.
· 2013
[cited by applicant]
US 8614255B2
· Blizzard et al.
· 2013
[cited by applicant]
US 8623419B2
· Malakhov et al.
· 2014
[cited by applicant]
US 8771744B2
· Ruecroft et al.
· 2014
[cited by applicant]
US 8790648B2
· Tocker et al.
· 2014
[cited by applicant]
US 8795634B2
· Illum et al.
· 2014
[cited by applicant]
US 8940683B2
· Levitt
· 2015
[cited by applicant]
US 8985102B2
· Hodson et al.
· 2015
[cited by applicant]
US 8997799B2
· Hodson et al.
· 2015
[cited by applicant]
US 9051302B2
· Winssinger et al.
· 2015
[cited by applicant]
US 9061352B2
· Lipp et al.
· 2015
[cited by applicant]
US 9085632B2
· Coates et al.
· 2015
[cited by applicant]
US 9101539B2
· Nagata et al.
· 2015
[cited by applicant]
US 9125999B2
· Rolfs et al.
· 2015
[cited by applicant]
US 9138407B2
· Caponetti et al.
· 2015
[cited by applicant]
US 9757395B2
· Yadidi
· 2017
[cited by examiner]
US 9757529B2
· Yadidi
· 2017
[cited by examiner]
US 9993488B2
· Yadidi
· 2018
[cited by examiner]
US 20030176421A1
· Watson et al.
· 2003
[cited by applicant]
US 20030186843A1
· Staniforth et al.
· 2003
[cited by applicant]
US 20030232019A1
· Basu et al.
· 2003
[cited by applicant]
US 20040049022A1
· Nyce et al.
· 2004
[cited by applicant]
US 20040092470A1
· Leonard et al.
· 2004
[cited by applicant]
US 20040105821A1
· Bernstein et al.
· 2004
[cited by applicant]
US 20050004079A1
· Benjamin et al.
· 2005
[cited by applicant]
US 20050148555A1
· Gupta et al.
· 2005
[cited by applicant]
US 20050249697A1
· Uhrich et al.
· 2005
[cited by applicant]
US 20060002995A1
· Harwigsson
· 2006
[cited by applicant]
US 20060030550A1
· Lithgow et al.
· 2006
[cited by applicant]
US 20060257987A1
· Gonzalez Valcarcel et al.
· 2006
[cited by applicant]
US 20060293217A1
· Barker et al.
· 2006
[cited by applicant]
US 20070003615A1
· Jenkins et al.
· 2007
[cited by applicant]
US 20070072939A1
· Kupper
· 2007
[cited by applicant]
US 20070116761A1
· Desai et al.
· 2007
[cited by applicant]
US 20070123571A1
· Raj et al.
· 2007
[cited by applicant]
US 20070178166A1
· Bernstein et al.
· 2007
[cited by applicant]
US 20070232575A1
· Baulieu et al.
· 2007
[cited by applicant]
US 20080066741A1
· LeMahieu et al.
· 2008
[cited by applicant]
US 20080127972A1
· Morton
· 2008
[cited by applicant]
US 20080220078A1
· Morton et al.
· 2008
[cited by applicant]
US 20090011030A1
· Jouhikainen et al.
· 2009
[cited by applicant]
US 20090110679A1
· Li et al.
· 2009
[cited by applicant]
US 20090136561A1
· Von Rechenberg et al.
· 2009
[cited by applicant]
US 20090220435A1
· Quay et al.
· 2009
[cited by applicant]
US 20090312380A1
· Becker
· 2009
[cited by applicant]
US 20100168710A1
· Braithwaite
· 2010
[cited by applicant]
US 20100234442A1
· Duarte-Vazquez et al.
· 2010
[cited by applicant]
US 20100258118A1
· Morton
· 2010
[cited by applicant]
US 20100319694A1
· Cook et al.
· 2010
[cited by applicant]
US 20110038931A1
· Kim et al.
· 2011
[cited by applicant]
US 20110112134A1
· Hutchinson et al.
· 2011
[cited by applicant]
US 20110142914A1
· Persaud et al.
· 2011
[cited by applicant]
US 20110189106A1
· Danzig et al.
· 2011
[cited by applicant]
US 20110200657A1
· Baker
· 2011
[cited by applicant]
US 20110263610A1
· Wan et al.
· 2011
[cited by applicant]
US 20120046251A1
· Schaefer et al.
· 2012
[cited by applicant]
US 20120125325A1
· Bannister et al.
· 2012
[cited by applicant]
US 20120276193A1
· Graversen et al.
· 2012
[cited by applicant]
US 20120306613A1
· De La Rue et al.
· 2012
[cited by applicant]
US 20120308566A1
· Martin et al.
· 2012
[cited by applicant]
US 20120308613A1
· Staniforth et al.
· 2012
[cited by applicant]
US 20130004969A1
· Peschon et al.
· 2013
[cited by applicant]
US 20130028942A1
· Surber et al.
· 2013
[cited by applicant]
US 20130316001A1
· Popov et al.
· 2013
[cited by applicant]
US 20140079784A1
· Burnier et al.
· 2014
[cited by applicant]
US 20140234330A1
· Budelsky et al.
· 2014
[cited by applicant]
US 20140239525A1
· Mcconville et al.
· 2014
[cited by applicant]
US 20140242174A1
· Walker
· 2014
[cited by applicant]
US 20140322238A1
· Budelsky et al.
· 2014
[cited by applicant]
US 20150005230A1
· Eliasof
· 2015
[cited by applicant]
US 20150050713A1
· Malakhov et al.
· 2015
[cited by applicant]
US 20150059746A1
· Green
· 2015
[cited by applicant]
US 20150093338A1
· Farber
· 2015
[cited by applicant]
US 20150136130A1
· Dehaan et al.
· 2015
[cited by applicant]
US 20150224129A1
· Trottein et al.
· 2015
[cited by applicant]
US 20150284381A1
· Andresen et al.
· 2015
[cited by applicant]
CA 1246597A
· 1988
[cited by applicant]
CN 102058886A
· 2011
[cited by applicant]
CN 105007731A
· 2015
[cited by applicant]
CN 105833399A
· 2016
[cited by applicant]
CN 106102748A
· 2016
[cited by applicant]
CN 106619549A
· 2017
[cited by applicant]
CN 107072947A
· 2017
[cited by applicant]
EP 0200628A1
· 1986
[cited by applicant]
EP 1177805A1
· 2022
[cited by applicant]
JP 61140520A
· 1987
[cited by applicant]
JP 2002529498A
· 2002
[cited by applicant]
JP 2003530425A
· 2003
[cited by applicant]
JP 2004514504A
· 2004
[cited by applicant]
JP 2008521788A
· 2008
[cited by applicant]
JP 2011201904A
· 2011
[cited by applicant]
JP 2015508808A
· 2015
[cited by applicant]
JP 2017506252A
· 2017
[cited by applicant]
JP 2017523189A
· 2017
[cited by applicant]
JP 2021502954A
· 2021
[cited by applicant]
KR 1020050114720A
· 2005
[cited by applicant]
KR 1020150041608A
· 2015
[cited by applicant]
KR 1020170039255A
· 2017
[cited by applicant]
WO WO0027359A1
· 2000
[cited by applicant]
WO WO03047598A1
· 2003
[cited by applicant]
WO WO03047628A1
· 2003
[cited by applicant]
WO WO2005040163A1
· 2005
[cited by applicant]
WO WO2005041886A2
· 2005
[cited by applicant]
WO WO2006017354A1
· 2006
[cited by applicant]
WO WO2007072503A2
· 2007
[cited by applicant]
WO WO2009019598A2
· 2009
[cited by applicant]
WO WO2012041717A1
· 2012
[cited by examiner]
WO WO2012107364A1
· 2012
[cited by applicant]
WO WO2012107765A2
· 2012
[cited by applicant]
WO WO2013004999A1
· 2013
[cited by applicant]
WO WO2014131851A1
· 2014
[cited by applicant]
WO WO2014155103A1
· 2014
[cited by applicant]
WO WO2015002703A1
· 2015
[cited by applicant]
WO WO2015011244A1
· 2015
[cited by applicant]
WO WO2015054574A1
· 2015
[cited by applicant]
WO WO2015096668A1
· 2015
[cited by applicant]
WO WO2015127315A1
· 2015
[cited by applicant]
WO WO2015148415A2
· 2015
[cited by applicant]
WO WO2015153838A1
· 2015
[cited by applicant]
WO WO2015155544A1
· 2015
[cited by applicant]
WO WO2016019253A1
· 2016
[cited by applicant]
WO WO2016160370A1
· 2016
[cited by applicant]
Moody “Clopidogrel (Plavix) is Not an Anticoagulant” 2023, https://www.maine.gov/ems/sites/maine.gov.ems/files/inline-files/20230920-MSA-Plavix.pdf (accessed Aug. 9, 2024) (Year: 2023).
[cited by examiner]
Kelly “Determination of the Decomposition of Aspirin” Journal of Pharmaceutical Sciences 1970, 59, 1053-1079 (Year: 1970).
[cited by examiner]
Japanese Office Action issued Feb. 21, 2022 in Japanese Patent Application No. 2020-516655 (with English translation), 8 pages.
[cited by applicant]
Tita, D., et al., “Compatibility study of the acetylsalicylic acid with different solid dosage forms excipients”, Journal of Thermal Analysis and Calorimetry, vol. 112, 2013, pp. 407-419.
[cited by applicant]
Ahlneck, C., et al., “Difference in Effect of Powdered and Granular Magnesium Stearate on the Solid State Stability of Acetylsalicylic Acid”, Acta Pharmaceutica Technologica, vol. 33, 1987, pp. 21-26.
[cited by applicant]
Combined Chinese Office Action and Search Report issued Oct. 9, 2021 in Chinese Patent Application No. 201780095045.3 (with English translation), 20 pages.
[cited by applicant]
Notice of Allowance issued Dec. 6, 2022, in corresponding Korean Patent Application No. 10-2020-7011576 (with English Translation), 3 pages.
[cited by applicant]
Korean Office Action issued Jan. 19, 2022 in Korean Patent Application No. 10-2020-7011578 (with English translation), 15 pages.
[cited by applicant]
Japanese Search Report issued Jun. 17, 2021 in Japanese Patent Application No. 2020-516655 (with English translation), 27 pages.
[cited by applicant]
Clark, A.R., et al.. “The Relationship Between Power Inhaler Resistance and Peak Inspiration Conditions in Healthy Volunteers—implications for In Vitro Testing”, Journal of Aerosol Med, 1993, 6(2), p. 99-110.
[cited by applicant]
Dalby, R.N., et al., “Inhalation Aerosols Physical and Biological Basis for Therapy”, edited by Hickey, Informa Healthcare USA, 2007, p. 437.
[cited by applicant]
Dehaan, W.H., et al., “Predicting extrathoracic deposition from dry powder inhalers”, Journal of Aerosol Science, 2004, 35 (3), pp. 309-331.
[cited by applicant]
Geller, M.D., D.E., et al., “Development of an inhaled Dry-Powder Formulation of Tobramycin using PulmoSphere™ Technology”, J Aerosol Med Pulm Drug Deliv. Aug. 2011; 24(4), p. 175-82.
[cited by applicant]
Gonda, I., “Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract”, in Critical Reviews in Therapeutic 10 Drug Carrier Systems, 1990, vol. 6, pp. 273-313.
[cited by applicant]
Hadinoto, K., et al., “Drug Release Study of Large Hollow Nanoparticulate Aggregates Carrier Particles for Pulmonary Delivery”, International Journal of Pharmaceutics, 2007, 341(1-2), p. 195-206.
[cited by applicant]
Kupczyk, M., et al. “Lipoxin A4 Generation is Decreased in Aspirin-Sensitive Patients in Lysine-Aspirin Nasal Challenge in Vivo Model”, Allergy (Oxford, United Kingdom), 2009, 64(12), p. 1746-1752.
[cited by applicant]
Moren, F., et al., “Aerosol Dosage Forms and Formulations”, Aerosols in Medicine, Principles, Diagnosis and Therapy, 1985, pp. 261-287, Esevier Science Publishers B.V., Amsterdam.
[cited by applicant]
Stank, K., et al., “Physico-chemical characterization of surface modified particles for inhalation”, International Journal of Pharmaceutics, 2013, 448: pp. 9-18.
[cited by applicant]
Tiddens, H.A., et al., “Effect of Dry Powder Inhaler Resistance on the Inspiratory Flow Rates and Volumes of Cystic Fibrosis Patients of Six Years and Older”, Journal of Aerosol Med, 2006, 19, (4), p. 456-465.
[cited by applicant]
USP Bulk Density and Tapped Density, United States Pharmacopeia convention, Rockville, MD, 10th Supplement, 1999, p. 4950-4951 with cover pages.
[cited by applicant]
USP Section 30 601 Aerosols, Metered-Dose Inhalers and Dry Powder Inhalers, Delivered-Dose Uniformity, Sampling the Delivered Dose from Dry Powder Inhalers, United States Pharmacopeia Convention, 2007, 13th Revision, p.…
[cited by applicant]
Connors et al., “Chemical Stability of Pharmaceuticals”, A Handbook for Pharmacists, Oct. 1986, 864 pages, 2nd Edition.
[cited by applicant]
Bharate, S. B., et al., “Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review,” J. Excipients and Food Chem., Nov. 3, 2010, pp. 3-26, 1(3).
[cited by applicant]
Li, J., et al., “Lubricants in Pharmaceutical Solid Dosage Forms”, Lubricants, Feb. 25, 2014, pp. 21-43, 2.
[cited by applicant]
Swaminathan, V., et al., Effect of Magnesium Stearate on the Content Uniformity of Active Ingredient in Pharmaceutical Powder Mixtures, AAPS PharmSciTech 2002, pp. 1-5, 3(3), Article 19, https://www.ncbi.nim.nih.govipmc…
[cited by applicant]
International Search Report and Written Opinion issued Nov. 27, 2017 in PCT/US17/53569, 9 pages.
[cited by applicant]
Japanese Office Action issued Jul. 27, 2023 in Japanese Application 2022-098813, (with unedited computer-generated English translation), 11 pages.
[cited by applicant]